Neuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital
Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity
Neuraxpharm Group (“Neuraxpharm”), the leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced today that it has signed a binding agreement to divest Inke, a specialized inhalation active pharmaceutical ingredients (APIs) developer and manufacturer, to Keensight Capital (“Keensight”), a leading private equity manager dedicated to pan-European Growth Buyout[1] investments.
